hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06389526, orgStudyIdInfo id: CHS-1000-01, briefTitle: A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-01, primaryCompletionDateStruct date: 2028-01-30, completionDateStruct date: 2028-01-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Coherus Biosciences, Inc., class: INDUSTRY, descriptionModule briefSummary: The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors., conditionsModule conditions: Advanced or Metastatic Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: CHS-1000, interventions name: Toripalimab, outcomesModule primaryOutcomes measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), secondaryOutcomes measure: Maximum Observed Concentration (Cmax), secondaryOutcomes measure: Area Under the Concentration-time Curve (AUC), secondaryOutcomes measure: Terminal Half-life (t1/2), secondaryOutcomes measure: Number of Participants with Antidrug Antibodies, secondaryOutcomes measure: Investigator-assessed Objective Response Rate (ORR), secondaryOutcomes measure: Duration of Response (DoR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Time to Response (TTP), secondaryOutcomes measure: Progression-free Survival (PFS), secondaryOutcomes measure: Landmark PFS Rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06389513, orgStudyIdInfo id: CTP-MCVF-005, briefTitle: Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: CanSino Biologics Inc., class: INDUSTRY, descriptionModule briefSummary: This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age., conditionsModule conditions: Epidemic Meningitis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 3000, type: ESTIMATED, armsInterventionsModule interventions name: MCV4, outcomesModule primaryOutcomes measure: Incidence of localized adverse reactions in subjects, primaryOutcomes measure: Incidence of systemic adverse reactions in subjects, secondaryOutcomes measure: Incidence of adverse reactions in subjects, secondaryOutcomes measure: Incidence of adverse events in subjects, secondaryOutcomes measure: Incidence of severe adverse events, eligibilityModule sex: ALL, minimumAge: 3 Months, maximumAge: 3 Months, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06389500, orgStudyIdInfo id: SHR-1316-HLJ-006, briefTitle: HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-05-01, completionDateStruct date: 2028-05-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Harbin Medical University, class: OTHER, descriptionModule briefSummary: This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract cancer., conditionsModule conditions: Biliary Tract Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab, interventions name: Lenvatinib, interventions name: Hepatic Arterial Infusion Chemotherapy, outcomesModule primaryOutcomes measure: R0 resection rate, primaryOutcomes measure: Surgery conversion rate, secondaryOutcomes measure: Objective response rate, secondaryOutcomes measure: pathological complete response rate, secondaryOutcomes measure: Major pathological response rate, secondaryOutcomes measure: Recurrence-free survival, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: AEs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06389461, orgStudyIdInfo id: OST1_012, briefTitle: 4th Ventricular Compression Technique on Anxiety, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-16, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Escola Superior de Tecnologia da Saúde do Porto, class: OTHER, descriptionModule briefSummary: Determinate the effects of the technique of 4th ventricle in college students with anxiety, applying the technique one time per week during three weeks., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: 4th Ventricular Compression Technique, interventions name: "Sham" Therapy, outcomesModule primaryOutcomes measure: Change from baseline in anxiety levels through the STAI (The State-Trait Anxiety Inventory) questionnaire score on the 1st and last intervention., secondaryOutcomes measure: Change from baseline in thoraco-abdominal perimetry on the 1st and last intervention, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Escola Superior da Saúde do Porto, city: Porto, zip: 4200-072, country: Portugal, geoPoint lat: 41.14961, lon: -8.61099, hasResults: False
protocolSection identificationModule nctId: NCT06389448, orgStudyIdInfo id: pCLE vs EB 2024tj, briefTitle: Comparison of pCLE and EB in Gastric Lesion Diagnosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-11, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Huazhong University of Science and Technology, class: OTHER, descriptionModule briefSummary: This is a prospective multicenter comparative study, aiming to compare probe-based confocal laser endomicroscopy (pCLE) and endoscopic biopsies in the diagnosis of the whole specific gastric lesion especially for distinguishing low grade intraepithelial neoplasia (LGIN) from high grade intraepithelial neoplasia (HGIN) and create an endoscopic image database for the follow-up research., conditionsModule conditions: Low Grade Intraepithelial Neoplasia, conditions: High Grade Intraepithelial Neoplasia, conditions: Early Gastric Cancer, conditions: Gastric Intraepithelial Neoplasia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Participants undergo pCLE after pre-ESD assessment and before ESD resection., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 366, type: ESTIMATED, armsInterventionsModule interventions name: pCLE-gastr, outcomesModule primaryOutcomes measure: Diagnostic accuracy of pCLE and endoscopic biopsy in diagnosing the whole gastric lesion, secondaryOutcomes measure: The histological upstaging rate of pCLE and endoscopic biopsy in diagnosing the whole gastric lesion, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology, status: RECRUITING, city: Wuhan, state: Hubei, zip: 430030, country: China, contacts name: Bin Cheng, Professor, role: CONTACT, phone: 86-027-8366-3333, email: bcheng@tjh.tjmu.edu.cn, contacts name: Yilin Gu, role: CONTACT, phone: 86-19884836004, email: yilingu2019@163.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06389422, orgStudyIdInfo id: NCC4620, briefTitle: Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2027-04-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, class: OTHER, descriptionModule briefSummary: This is a single-center, single-arm, open-label study that includes patients meeting the inclusion criteria (liver-GTV volume \< 700ml or estimated liver-GTV V5 \< 300ml) with hepatocellular carcinoma with diffuse tumor thrombosis involving both left and right lobes. All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center. One week before or during the radiotherapy, patients receive concurrent Pembrolizumab at a dose of 200mg. Subsequently, Pembrolizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Pembrolizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance. The primary endpoint is median overall survival (mOS), and secondary endpoints include objective response rate (ORR), progression-free survival (PFS), and toxicity., conditionsModule conditions: Hepatocellular Carcinoma, conditions: Radiotherapy, conditions: Pembrolizumab, conditions: Tumor Thrombosis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, interventions name: Pembrolizumab, outcomesModule primaryOutcomes measure: Median Overall Survival, secondaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Progression-free Survival, secondaryOutcomes measure: Toxicity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciecnces and Peking Union Medical College, status: RECRUITING, city: Beijing, state: Beijing, country: China, contacts name: Bo Chen, MD, role: CONTACT, phone: 0086-13240000876, email: chenboo@outlook.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06389409, orgStudyIdInfo id: Protocollo N.2009 Testicolo, briefTitle: Study on the Quality of Life and Functional/Oncological Outcome of Testicular Cancer Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2010-08-24, primaryCompletionDateStruct date: 2030-09-01, completionDateStruct date: 2040-08-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: IRCCS San Raffaele, class: OTHER, descriptionModule briefSummary: The research aims to collect data in order to report the main problems related to the testicular cancer; To reach this aim, this study proposes to create a database of the testicular cancer condition.From this perspective, the aim of this project is the improving of scientific knowledge of the disease and develop appropriate and effective procedures for the diagnosis and treatment of the patient., conditionsModule conditions: Testicular Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3000, type: ESTIMATED, armsInterventionsModule interventions name: Observation of testicular cancer patients, outcomesModule primaryOutcomes measure: Clinical data, primaryOutcomes measure: Adjuvant therapy, primaryOutcomes measure: lactate dehydrogenase, primaryOutcomes measure: Testicular objective examination, primaryOutcomes measure: Testicular objective examination - cysts, primaryOutcomes measure: Testicular objective examination - nodules, primaryOutcomes measure: Testicular objective examination - varicocele, primaryOutcomes measure: Testicular objective examination - hydrocele, primaryOutcomes measure: α-feto protein, primaryOutcomes measure: β human Chorionic Gonadotropin, primaryOutcomes measure: carcinoembryonic antigen, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Ospedale San Raffaele, status: RECRUITING, city: Milan, state: Lombardy, zip: 20132, country: Italy, contacts name: Alessia d'Arma, PhD, role: CONTACT, phone: 02 2643 5506, email: darma.alessia@hsr.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06389396, orgStudyIdInfo id: CP362, briefTitle: Investigation of a New Rectal Catheter for Users of Transanal Irrigation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Coloplast A/S, class: INDUSTRY, descriptionModule briefSummary: The clinical investigation is an exploratory, randomised controlled, open-labelled, crossover investigation.The clinical investigation will be conducted as a multi-centre clinical investigation in two different clinical investigation sites in Denmark., conditionsModule conditions: Bowel Management, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: CP362 Test Catheter, outcomesModule primaryOutcomes measure: The primary endpoint is: Was it possible to perform transanal irrigation (assessed after irrigation at V1 and V2), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Århus Universitetshospital, status: RECRUITING, city: Århus, state: Jutland, zip: 8200, country: Denmark, contacts name: Peter Christensen, role: CONTACT, geoPoint lat: 56.15674, lon: 10.21076, locations facility: Amager Hvidovre Hospital, status: RECRUITING, city: Hvidovre, state: Zealand, zip: 2650, country: Denmark, contacts name: Michael Sørensen, role: CONTACT, geoPoint lat: 55.65719, lon: 12.47364, hasResults: False
protocolSection identificationModule nctId: NCT06389383, orgStudyIdInfo id: 22-0182, briefTitle: Pilot Study - Monitoring the Nasal Microbiome and Viral Respiratory Infections in Newborn Hospitalized in Neonatalogy., acronym: NEONATMICROBIO, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-12-21, primaryCompletionDateStruct date: 2023-06-30, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: University Hospital, Caen, class: OTHER, descriptionModule briefSummary: The objective of our study is therefore to study the evolution of the respiratory microbiome of hospitalized newborns, its interaction with viral infections and their impacts on the evolution of newborns., conditionsModule conditions: Newborn; Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 38, type: ACTUAL, armsInterventionsModule interventions name: Nasal Swab, outcomesModule primaryOutcomes measure: rate of viral infections, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CAEN University Hospital, city: Caen, country: France, geoPoint lat: 49.18585, lon: -0.35912, hasResults: False
protocolSection identificationModule nctId: NCT06389370, orgStudyIdInfo id: knowledge, Attitude, Behaviour, briefTitle: ASSESSMENT OF ORAL HEALTH KNOWLEDGE, ATTITUDE AND BEHAVIOUR AND ITS ASSOCIATION WITH SOCIODEMOGRAPHIC FACTORS OF PRECLINICAL AND CLINICAL DENTAL STUDENTS IN CAIRO UNIVERSITY: A CROSS-SECTIONAL STUDY, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-11-04, primaryCompletionDateStruct date: 2024-11-18, completionDateStruct date: 2024-12-03, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The knowledge, behaviour and attitude of oral health professionals reflects their awareness and understanding of oral preventive measures, which will have significant impact on their delivery of public oral health promotion in the future. They are expected to set an example for positive oral health behaviour among other college students, family members and their patients. Various external factors like sociodemographic factors like age, gender, marital state, occupation, and number of family members play a major role in oral hygiene. The relationships between various modifiable factors needs to be assesses in a vast manner.There were some researches about oral health knowledge, behaviour and attitude in correlation to socio-demographic data, of dental students in other countries, but little was known in Egypt. Dental students are expected to play a critical role in instructing public oral health for improving their patient's, families, and friends. In addition, it may pave the way to develop new programs to encourage needful oral health practices., conditionsModule conditions: Oral Health Knowledge, Attitude and Behaviour of Dental Students, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 535, type: ESTIMATED, armsInterventionsModule interventions name: HU-DBI questionnaire, outcomesModule primaryOutcomes measure: Increase of dental students KAB by preceding through higher academic levels, eligibilityModule sex: ALL, minimumAge: 17 Years, maximumAge: 27 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06389357, orgStudyIdInfo id: 1305G2024, briefTitle: Return to School Adaptation Programme for Children With Cancer, acronym: web-based, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2024-09-06, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Gazi University, class: OTHER, descriptionModule briefSummary: This study is planned to evaluate the effect of back-to-school adaptation programme on social anxiety score, coping score and back-to-school readiness score in children aged 8-17 years who are followed up with a diagnosis of cancer.H1: Is there a significant difference in children's social anxiety scores before and after the back-to-school adaptation programme? H2: Is there a significant difference in children's coping scores before and after the back-to-school adaptation programme? H3: Is there a significant difference in children's readiness to return to school scores before and after the back-to-school adaptation programme?, conditionsModule conditions: Childhood Cancer, conditions: ALL, Childhood, conditions: AML, Childhood, conditions: Lymphoma, conditions: Solid Tumor, Childhood, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The research is a technical/scientific/collaborative action research design., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: training and counselling, outcomesModule primaryOutcomes measure: social anxiety, primaryOutcomes measure: coping, primaryOutcomes measure: back to school readiness, secondaryOutcomes measure: process evaluation, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Gizem Cakir, city: Ankara, state: Cankaya, zip: 06490, country: Turkey, contacts name: Gizem Cakir, PhD(c), role: CONTACT, phone: +905300858879, email: cakirgzem@gmail.com, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False